1312786-97-2

Upstream product

• 1312788-49-0 5-chloroisothiazol-3-ol 1-oxide 
• 1312788-48-9 4-(5-(3-((4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenoxy)methyl)-2-methylphenyl)-4-methylpyridin-2-yloxy)-2-methylbutan-2-ol 
• 1294453-67-0 5,5-dimethyl-2-(2-methyl-3-((tetrahydro-2H-pyran-2-yloxy)methyl)phenyl)-1,3,2-dioxaborinane 
• 955931-17-6 (3-(6-(3-hydroxy-3-methylbutoxy)-4-methylpyridin-3-yl)-2-methylphenyl)methanol 
• 1192765-29-9 4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenol 
• 955930-01-5 4-[(5-bromo-4-methylpyridin-2-yl)oxy]2-methylbutan-2-ol 
• 17689-66-6 3-hydroxy-3-methylbutyl toluene-4-sulfonate 
• 164513-38-6 2-hydroxy-5-bromo-4-methylpyridine 
• 134638-86-1 2-((3-bromo-2-methylphenyl)methoxy)tetrahydro-2H-pyran 
• 83647-43-2 3-bromo-2-methylbenzyl alcohol 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 

Relevant academic research and scientific papers

NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR7—; and R1 to R7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.